Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2014 Jan;14(1):7.
doi: 10.1038/nrc3653.

Therapeutics: delving deeper into resistance

Sarah Seton-Rogers
Comment

Therapeutics: delving deeper into resistance

Sarah Seton-Rogers. Nat Rev Cancer. 2014 Jan.
No abstract available

PubMed Disclaimer

Comment on

  • A melanocyte lineage program confers resistance to MAP kinase pathway inhibition.
    Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Donahue MK, Narayan R, Flaherty KT, Wargo JA, Root DE, Garraway LA. Johannessen CM, et al. Nature. 2013 Dec 5;504(7478):138-42. doi: 10.1038/nature12688. Epub 2013 Nov 3. Nature. 2013. PMID: 24185007 Free PMC article.
  • A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.
    Shi H, Hong A, Kong X, Koya RC, Song C, Moriceau G, Hugo W, Yu CC, Ng C, Chodon T, Scolyer RA, Kefford RF, Ribas A, Long GV, Lo RS. Shi H, et al. Cancer Discov. 2014 Jan;4(1):69-79. doi: 10.1158/2159-8290.CD-13-0279. Epub 2013 Nov 21. Cancer Discov. 2014. PMID: 24265152 Free PMC article.
  • The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.
    Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, Place CS, Taylor-Weiner A, Whittaker S, Kryukov GV, Hodis E, Rosenberg M, McKenna A, Cibulskis K, Farlow D, Zimmer L, Hillen U, Gutzmer R, Goldinger SM, Ugurel S, Gogas HJ, Egberts F, Berking C, Trefzer U, Loquai C, Weide B, Hassel JC, Gabriel SB, Carter SL, Getz G, Garraway LA, Schadendorf D; Dermatologic Cooperative Oncology Group of Germany (DeCOG). Van Allen EM, et al. Cancer Discov. 2014 Jan;4(1):94-109. doi: 10.1158/2159-8290.CD-13-0617. Epub 2013 Nov 21. Cancer Discov. 2014. PMID: 24265153 Free PMC article.
  • MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
    Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, Rosenberg M, Goetz EM, Sullivan RJ, Farlow DN, Friedrich DC, Anderka K, Perrin D, Johannessen CM, McKenna A, Cibulskis K, Kryukov G, Hodis E, Lawrence DP, Fisher S, Getz G, Gabriel SB, Carter SL, Flaherty KT, Wargo JA, Garraway LA. Wagle N, et al. Cancer Discov. 2014 Jan;4(1):61-8. doi: 10.1158/2159-8290.CD-13-0631. Epub 2013 Nov 21. Cancer Discov. 2014. PMID: 24265154 Free PMC article. Clinical Trial.
  • Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.
    Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS. Shi H, et al. Cancer Discov. 2014 Jan;4(1):80-93. doi: 10.1158/2159-8290.CD-13-0642. Epub 2013 Nov 21. Cancer Discov. 2014. PMID: 24265155 Free PMC article.

References

    1. Cancer Discov. 2014 Jan;4(1):69-79 - PubMed
    1. Cancer Discov. 2014 Jan;4(1):94-109 - PubMed
    1. Cancer Discov. 2014 Jan;4(1):80-93 - PubMed
    1. Cancer Discov. 2014 Jan;4(1):61-8 - PubMed
    1. Nature. 2013 Dec 5;504(7478):138-42 - PubMed

MeSH terms

Substances

LinkOut - more resources